Based on the Brainstorm Cell Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Brainstorm Cell Therapeutics Inc is not available over the next 12 months. Brainstorm Cell Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Brainstorm Cell Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Brainstorm Cell Therapeutics Inc’s stock price was USD 2.02. Brainstorm Cell Therapeutics Inc’s stock price has changed by -9.42% over the past week, +26.25% over the past month and -58.80% over the last year.
No recent analyst target price found for Brainstorm Cell Therapeutics Inc
No recent average analyst rating found for Brainstorm Cell Therapeutics Inc
Company Overview Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. Read Less
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture...Read More
Frequently Asked Questions About Brainstorm Cell Therapeutics Inc (BCLI) Stock
Stock Target Advisor's fundamental analysis for Brainstorm Cell Therapeutics Inc's stock is Very Bearish.
Unfortunately we do not have enough data on BCLI's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BCLI's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BCLI's stock to indicate if its overvalued.
The last closing price of BCLI's stock was USD 2.02.
The most recent market capitalization for BCLI is USD 0.01B.
Unfortunately we do not have enough analyst data on BCLI's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Brainstorm Cell Therapeutics Inc's stock.
As per our most recent records Brainstorm Cell Therapeutics Inc has 29 Employees.
Brainstorm Cell Therapeutics Inc's registered address is 1325 Avenue of Americas, New York, NY, United States, 10019.
You can get more information about it from Brainstorm Cell Therapeutics Inc's website at https://www.brainstorm-cell.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Brainstorm Cell Therapeutics Inc (BCLI) Stock
Stock Target Advisor's fundamental analysis for Brainstorm Cell Therapeutics Inc's stock is Very Bearish.
Unfortunately we do not have enough data on BCLI's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BCLI's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BCLI's stock to indicate if its overvalued.
The last closing price of BCLI's stock was USD 2.02.
The most recent market capitalization for BCLI is USD 0.01B.
Unfortunately we do not have enough analyst data on BCLI's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Brainstorm Cell Therapeutics Inc's stock.
As per our most recent records Brainstorm Cell Therapeutics Inc has 29 Employees.
Brainstorm Cell Therapeutics Inc's registered address is 1325 Avenue of Americas, New York, NY, United States, 10019.
You can get more information about it from Brainstorm Cell Therapeutics Inc's website at https://www.brainstorm-cell.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BCLI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
